PSTX News and Press, Poseida Therapeutics Inc. From 11/10/23

2023-11-10 10:48:08 ET More on Poseida Therapeutics Poseida Therapeutics: Why I Am Still Holding On To The Stock Into 2024 (Rating Downgrade) Poseida Therapeutics' Financial And Clinical Milestones Signal Upgrade To 'Strong Buy' Poseida Therapeutics, Inc. 2023 Q2 - R...

Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2023 PR Newswire Based upon progress in its allogeneic programs, the Company is announcing today acceleration and increased certainty of achieving upcoming milestones and payments related to t...

Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...

Poseida Therapeutics Inc. (PSTX) is expected to report $-0.28 for Q3 2023

Poseida Therapeutics to Present at the 65th ASH Annual Meeting and Exposition PR Newswire SAN DIEGO , Nov. 2, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for pa...

2023-10-11 17:30:06 ET Gainers: COMPASS Pathways  ( NASDAQ: CMPS ) +5% . Inozyme Pharma ( INZY ) +4% . CommScope Holding ( COMM ) +4% . FTAI Infrastructure ( FIP ) +3% . Aemetis ( AMTX ) +3% . Losers: Lottery ( ...

2023-10-10 18:08:38 ET Gainers: VOXX International  ( VOXX ) +10% . BioAtla ( BCAB ) +6% . Poseida Therapeutics ( PSTX ) +5% . Diversified Healthcare  ( DHC ) +5% . Alignment Healthcare ( ALHC ) +4% . Losers: Si...

2023-10-09 16:49:24 ET More on Poseida Therapeutics Poseida Therapeutics: Why I Am Still Holding On To The Stock Into 2024 (Rating Downgrade) Poseida Therapeutics' Financial And Clinical Milestones Signal Upgrade To 'Strong Buy' Poseida jumps on $50M investment from ...

Poseida Therapeutics Announces Leadership Transition PR Newswire Mark Gergen to assume role of Executive Chairman of the Board of Directors of Poseida; Kristin Yarema , Ph.D., currently President, Cell Therapy, to be appointed President and CEO SAN DIEGO ...

2023-10-04 02:20:41 ET Summary Poseida Therapeutics reported strong Q2 2023 revenue growth of 641.22% YoY, beating estimates by $14.93 million. Astellas Pharma's $50 million investment in Poseida's cancer cell therapy is a positive step after the termination of its collaboration w...